BR0110618A - Composição farmacêutica similar a gel para administraçâo subcutânea compreendendo ácidos bis-fosfÈnicos ou seus sais - Google Patents

Composição farmacêutica similar a gel para administraçâo subcutânea compreendendo ácidos bis-fosfÈnicos ou seus sais

Info

Publication number
BR0110618A
BR0110618A BR0110618-0A BR0110618A BR0110618A BR 0110618 A BR0110618 A BR 0110618A BR 0110618 A BR0110618 A BR 0110618A BR 0110618 A BR0110618 A BR 0110618A
Authority
BR
Brazil
Prior art keywords
salts
gel
bisphosphonic acids
pharmaceutical composition
subcutaneous administration
Prior art date
Application number
BR0110618-0A
Other languages
English (en)
Inventor
Rainer Bader
Petra Bastian
Wolfgang Roedel
Achim Goepferich
Gerhard Winter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0110618A publication Critical patent/BR0110618A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA SIMILAR A GEL PARA ADMINISTRAçãO SUBCUTâNEA COMPREENDENDO áCIDOS BIS-FOSFÈNICOS OU SEUS SAIS". A invenção refere-se a uma preparação farmacêutica para administração parenteral subcutânea, a qual contém ácidos bis-fosfónicos ou seus sais como substância ativa, bem como a produção desta preparação. Por meio da preparação de acordo com a invenção é possível administrar localmente concentrações relativamente altas de bisfosfonatos sem a ocorrência de incompatibilidades.
BR0110618-0A 2000-05-05 2001-04-23 Composição farmacêutica similar a gel para administraçâo subcutânea compreendendo ácidos bis-fosfÈnicos ou seus sais BR0110618A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10021917 2000-05-05
PCT/EP2001/004550 WO2001085217A1 (en) 2000-05-05 2001-04-23 Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts

Publications (1)

Publication Number Publication Date
BR0110618A true BR0110618A (pt) 2003-04-29

Family

ID=7640900

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110618-0A BR0110618A (pt) 2000-05-05 2001-04-23 Composição farmacêutica similar a gel para administraçâo subcutânea compreendendo ácidos bis-fosfÈnicos ou seus sais

Country Status (16)

Country Link
US (1) US6676970B2 (pt)
EP (1) EP1284754B1 (pt)
JP (1) JP3923800B2 (pt)
KR (1) KR100492110B1 (pt)
CN (1) CN1180846C (pt)
AR (2) AR033671A1 (pt)
AT (1) ATE314862T1 (pt)
AU (1) AU778431B2 (pt)
BR (1) BR0110618A (pt)
CA (1) CA2407747C (pt)
DE (1) DE60116483T2 (pt)
DK (1) DK1284754T3 (pt)
ES (1) ES2254410T3 (pt)
MX (1) MXPA02010740A (pt)
WO (1) WO2001085217A1 (pt)
ZA (1) ZA200208499B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151876A1 (en) * 2001-02-07 2002-10-17 Tai-Wah Chan Devices and methods for management of bone density
US7875597B2 (en) * 2002-07-24 2011-01-25 New York University Treatment of spinal mechanical pain
CN100364544C (zh) * 2004-07-21 2008-01-30 上海第二医科大学附属瑞金医院 一种携带二氯亚甲基二膦酸的明胶微粒及制备方法
EP1713489B1 (en) * 2004-08-23 2011-01-19 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium and processes for preparation thereof
US7294195B2 (en) * 2005-08-08 2007-11-13 Wacker Chemical Corporation Water repellant gypsum compositions
ITMI20052515A1 (it) * 2005-12-29 2007-06-30 Abiogen Pharma Spa Formulazione farmaceutica per il trattamento della osteoartrite
EP1923049A1 (en) * 2006-11-17 2008-05-21 Besins Healthcare Pharmaceutical compositions comprising a bisphosphonate compound
EP2114368A1 (en) * 2006-11-17 2009-11-11 Besins Healthcare Pharmaceutical compositions comprising a bisphosphonate compound
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
EP1992364A1 (en) * 2007-05-16 2008-11-19 Biosuma S.r.l. Carboxylated polysaccharides phosphated or bisphosphonated derivatives, optionally cross-linked, and their preparation and biomedical uses
WO2009128918A1 (en) * 2008-04-14 2009-10-22 Halozyme, Inc. Combination therapy using a soluble hyaluronidase and a bisphosphonate
US20100247607A1 (en) * 2009-03-26 2010-09-30 Psivida Us, Inc. Implantable formulations of bisphosphonic acids
ES2650665T3 (es) * 2009-07-31 2018-01-19 Grünenthal GmbH Método de cristalización y biodisponibilidad
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CN102000094B (zh) * 2010-09-27 2013-03-27 天津南开允公医药科技有限公司 一种含有伊班膦酸的药物组合物及制备工艺
WO2012048285A1 (en) * 2010-10-08 2012-04-12 Lanco Biosciences, Inc. Delivery of bisphosphonates by microinjection systems
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
GB201412236D0 (en) * 2014-07-09 2014-08-20 Univ Nottingham Method of producing and using alginate hydrogels
EP3189852B1 (en) * 2014-09-03 2021-04-07 Nitto Denko Corporation Bisphosphonate-containing pharmaceutical vaccine composition for humoral immunity
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
IT201800009444A1 (it) 2018-10-15 2020-04-15 Fidia Farm Spa Coniugati tra acido ialuronico e amminobisfosfonati e loro impiego terapeutico

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE61111C (de) B. WINKLER in Berka a. Werrä Verfahren zur Herstellung von Knöpfen ohne Fadenbefestigung
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922077A (en) 1989-01-31 1990-05-01 Raytheon Company Method of laser marking metal packages
CA2035179C (en) * 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
DE4223940A1 (de) * 1992-07-21 1994-01-27 Boehringer Mannheim Gmbh Neue acyclische Amidingruppen-haltige Diphosphonsäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4228552A1 (de) * 1992-08-27 1994-03-03 Boehringer Mannheim Gmbh Diphosphonsäuren und deren Salze enthaltende Arzneimittel
DE4244423A1 (de) 1992-12-29 1994-06-30 Boehringer Mannheim Gmbh Wasserlösliche Calciumsalze der 1-Hydroxy-3-(methylpentylamino)propan-1,1-bisphosphonsäure, ihre Herstellung und Verwendung als Arzneimittel
DE4244422A1 (de) 1992-12-29 1994-06-30 Boehringer Mannheim Gmbh Schwerlösliche Zink- und Magnesiumsalze von 1,1-Bisphosphonsäuren, ihre Herstellung und Verwendung als Arzneimittel
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation

Also Published As

Publication number Publication date
AU778431B2 (en) 2004-12-02
CN1427727A (zh) 2003-07-02
AR055407A2 (es) 2007-08-22
ZA200208499B (en) 2004-02-26
CN1180846C (zh) 2004-12-22
JP3923800B2 (ja) 2007-06-06
CA2407747A1 (en) 2001-11-15
EP1284754B1 (en) 2006-01-04
KR20030009470A (ko) 2003-01-29
AR033671A1 (es) 2004-01-07
CA2407747C (en) 2008-03-11
ES2254410T3 (es) 2006-06-16
JP2003532689A (ja) 2003-11-05
KR100492110B1 (ko) 2005-06-02
DE60116483D1 (de) 2006-03-30
AU5631701A (en) 2001-11-20
ATE314862T1 (de) 2006-02-15
MXPA02010740A (es) 2003-03-10
EP1284754A1 (en) 2003-02-26
DE60116483T2 (de) 2006-09-07
US20010053388A1 (en) 2001-12-20
DK1284754T3 (da) 2006-05-01
US6676970B2 (en) 2004-01-13
WO2001085217A1 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
BR0110618A (pt) Composição farmacêutica similar a gel para administraçâo subcutânea compreendendo ácidos bis-fosfÈnicos ou seus sais
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
BRPI0411678A (pt) nanopartìculas de ácido hialurÈnico
BR0111126A (pt) Derivados de aminoácidos cìclicos úteis como agentes farmacêuticos
ES2244831T5 (es) Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
CY1109457T1 (el) Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει
BR0212251A (pt) Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica, método para o tratamento preventivo e/ou terapêutico de uma doença ou distúrbio decorrente de proliferação celular anormal ou imprópria, e, uso do dito composto ou de um sal farmaceuticamente aceitável do mesmo
BR0017067A (pt) Inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto
BR0316605A (pt) Derivados de fluorglicosìdeos aromáticos, medicamentos contendo estes compostos e sua aplicação
BR0211801A (pt) Derivados de 7h-pirrolo[2,3-d]pirimidina
AR024462A1 (es) Tabletas farmaceuticas
BRPI0400214A (pt) Composições e aplicações farmacêuticas para a obtenção confiável de nìveis aceitáveis de testosterona no soro
AR037560A1 (es) Formulacion de altas dosis de ibandronato
PT1140031E (pt) Preparacao farmaceutica de libertacao controlada com mesilato de tilidina como substancia activa
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
BRPI0416650A (pt) composição de lipossoma estável para a aplicação de um agente farmacêutico, composição de lipossoma estéril e estável para a aplicação de um agente farmacêutico método para a produção de uma composição de lipossoma estável para a aplicação de um agente farmacêutico, composição farmacêutica, uso de uma composição de lipossoma, dispositivo para conter uma composição de lipossoma estável, kit para a aplicação de um agente farmacêutico a um paciente, método para aumentar a estabilidade de composições de lipossomas, método para a identificação de uma composição de lipossoma estável na fase, composição de lipossoma e composição de lipossoma estável na fase
BR0110892A (pt) Forma de administração farmacêutica para peptìdios, processos para preparação e uso dos mesmos
WO2009087682A3 (en) Stabilized injectable formulation of pregabalin
BR0116060A (pt) Composição farmacêutica de dronedarona para administração parenteral
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
BRPI0416188A (pt) formulações de medicamentos que contêm aromatizante, com propriedades farmacêuticas aperfeiçoadas
BR0307009A (pt) Sais estáveis de ácido o-acetilsalicìlico com aminoácidos básicos ii
CA2641571A1 (en) Treatment of osteoarthritis

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2515 DE 19-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.